# Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

> **NCT05541510** · PHASE2,PHASE3 · TERMINATED · sponsor: **Advagene Biopharma Co. Ltd.** · enrollment: 180 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AD17002 + Formulation buffer
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05541510
- **Lead sponsor:** Advagene Biopharma Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-01
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-25
- **Target enrollment:** 180 (ACTUAL)
- **Why stopped:** The end of COVID-19 pandemic
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541510, "Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05541510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*